Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. antico ...
Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
Boston Scientific (NYSE:BSX) announced positive data from a randomized clinical trial evaluating its EKOS endovascular system.
Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endova ...
MedPage Today on MSN
In the hot seat at ACC: PE clot-buster, Impella-protected PCI, utility of CAC=0
Results of lung impedance-guided therapy in HFpEF also anticipated this weekend ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results